Regulus Therapeutics
RGLS
$2.42
Share price
6.61%
Change (1 day)
79.26%
Change (1 year)
Categories
Regulus Therapeutics (RGLS) - Cash on Hand
Cash on Hand as of September 2023 : $30.78 M
According to Regulus Therapeutics's latest financial reports the company has $30.78 M in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Regulus Therapeutics - Cash on Hand chart (from 2011 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2022-12-31 | $39.16 M | -35.15% |
| 2021-12-31 | $60.38 M | 94.24% |
| 2020-12-31 | $31.08 M | -8.89% |
| 2019-12-31 | $34.12 M | 144.86% |
| 2018-12-31 | $13.93 M | -76.8% |
| 2017-12-31 | $60.07 M | -21.07% |
| 2016-12-31 | $76.11 M | -33.27% |
| 2015-12-31 | $0.11 B | -28.6% |
| 2014-12-31 | $0.15 B | 40.12% |
| 2013-12-31 | $0.11 B | 16.21% |
| 2012-12-31 | $98.1 M | 157.18% |
| 2011-12-31 | $38.14 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | $9.92 B | 32,153.07% | 🇫🇷 France |
 Biogen BIIB | $1.04 B | 3,310.76% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $12.28 B | 39,793.44% | 🇺🇸 USA |
 AstraZeneca AZN | $5.86 B | 18,937.10% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $6.35 B | 20,544.60% | 🇬🇧 UK |
 Sangamo Therapeutics
SGMO | $81 M | 163.15% | 🇺🇸 USA |
 Dicerna Pharmaceuticals DRNA | N/A | N/A | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | $2.43 B | 7,824.70% | 🇺🇸 USA |